Literature DB >> 17895166

Views on the use of tissue plasminogen activator in acute ischemic stroke: a state-wide survey among neurologists and emergency medicine physicians in Indiana.

J F Meschia1, L S Williams, J D Fleck, A Bruno, J Biller.   

Abstract

Indiana emergency medicine physicians and neurologists were presented with 6 brief cases of patients presenting with acute ischemic stroke and asked whether they would administer tissue plasminogen activator (t-PA) in each case; 25% responded in concordance with published American Heart Association guidelines in all cases. Only 19% gave the appropriate exclusion in the 4 cases with definite exclusion criteria. Administering t-PA to a patient with elevated blood pressure was the most common deviation from the guidelines. More neurologists reported that they would have given t-PA in the exclusion-free scenario (85% v 49%; P<.001). Physicians likely to treat acute stroke patients do not consistently follow published guidelines on the use of intravenous t-PA in acute ischemic stroke. Neurologists were more likely to report that they would use t-PA in an exclusion-free scenario. Continued physician education about thrombolytic use in acute ischemic stroke is needed.

Entities:  

Year:  1999        PMID: 17895166     DOI: 10.1016/s1052-3057(99)80068-8

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  2 in total

1.  Emergency physician and stroke specialist beliefs and expectations regarding telestroke.

Authors:  Ari Moskowitz; Yu-Feng Yvonne Chan; John Bruns; Steven R Levine
Journal:  Stroke       Date:  2010-02-18       Impact factor: 7.914

Review 2.  Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.

Authors:  Sherita N Chapman; Prachi Mehndiratta; Michelle C Johansen; Timothy L McMurry; Karen C Johnston; Andrew M Southerland
Journal:  Vasc Health Risk Manag       Date:  2014-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.